SEATTLE, July  31, 2026  (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (&#34;Perspective&#34; or the &#34;Company&#34;) (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for

CATX

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

Perspective Therapeutics to announce Q2 results on August 10; focus on radiopharma pipeline

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SEATTLE, July  31, 2026  (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (&amp;#34;Perspective&amp;#34; or the &amp;#34;Company&amp;#34;) (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Perspective Therapeutics (CATX) will report Q2 2026 results and provide a business update on Aug 10 after the close. The company emphasizes its 212Pb alpha-therapy platform and programs VMT-α-NET, VMT01, PSV359, plus expanding a Ra-212Pb generator network to support trials and potential commercialization. No financial figures are disclosed, making guidance and risk factors the key near-term focus.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Perspective to report Q2 2026 results Aug 10 after market close.</li><li>Alpha-emitting 212Pb tech powers VMT-α-NET, VMT01, PSV359.</li><li>Expanding Ra-212Pb generator network to support trials and potential commercialization.</li><li>No financial figures provided; press release emphasizes forward-looking statements and risks.</li><li>IR contacts and newsroom link included for more information.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Perspective Therapeutics, Inc. (CATX)</strong>: NYSE-listed radiopharmaceutical company driving the announced Q2 update and pipeline.</li><li><strong>ENTENTE Network of Companies (N/A)</strong>: PR distribution partner mentioned; limited direct, price-relevant impact.</li></ul>
  </section>

  <section data-block="category">
    <h3>Earnings</h3>
    <p>Category: Earnings. The release centers on upcoming Q2 results and business update, with emphasis on the 212Pb theranostic platform and pipeline—key near-term drivers for CATX&#039;s valuation as trial progress and funding signals evolve.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Aug 10 Q2 results release is a near-term price driver.</li><li>Any updates on cash runway or funding could swing CATX.</li><li>Pipeline progress for VMT-α-NET, VMT01, PSV359 may re-rate valuation.</li><li>Ra-212Pb generator expansion could signal scalable manufacturing upside.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Q2 2026 results and business update scheduled for Aug 10, 2026 after market close.</li><li>Company uses 212Pb alpha-generating radiopharmaceutical platform.</li><li>Pipeline includes VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), PSV359 (solid tumors).</li><li>Generator platform supports Ra-224/Ra-212Pb supply for trials.</li><li>Press release date July 31, 2026; forward-looking statements with risk factors disclosed.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral near-term; catalysts hinge on Aug 10 results and pipeline updates.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">SEATTLE, July  31, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=mUeAs7MGzh0EmxdMuM6Ck2JVn81IgoUBdm973RMLazUrwmn5Vi_XIrEYUcupslGPiDz93vXBoILrS-Q3GrTtGDHlK956Opi-2HtgA8rQytueYAbqyvJEoVo-eNLHZiRd" rel="nofollow" target="_blank">Perspective Therapeutics, Inc.</a> (&#34;Perspective&#34; or the &#34;Company&#34;) (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/CATX">CATX</a>), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026 after the market closes. The press release will be available on the newsroom section of the Company&#39;s website at <a href="https://www.globenewswire.com/Tracker?data=Jw8GdnnEIpIsBxETGrzlZXFVJlkATmUk_heKXKilXuBJ3A2TdsyhiylVVQk4qpj4a-nBdyaHbbLNZtr4xAATTPCseTv6Wpkf3MPZZ26_57JibLJnTtpMWBX1V7nS0T4wch5C28XWQAg_Jg4Ufg1pSEslS8KFnKhnUtZ_e20nNbZKKzfMKkuoeCIJqhCX4m0xfIEtNCVBcyhuhjoVz-9VzXlMhqQCJ9e6zmKWsO5nVw3UWtOyDkod9t_j46KGBEIzUTufgIKnp-g7Il09jM3ZEzOad_JPA0Iiz2X07a_CA0VNtTuXsdjCgP1ZzFzz6zqCEbXkTCsSqB8sU52L8CgMAMbXmKWBWhTnXn_FNIM3vTo4CeqaDMRuVvKh1ZJ6GfX8siH1MPG-F5Y8Ymz6irj8BQipQ2tV8UZA5QCNZ5GWQ7HuS0MmeoAmbTSuRMuxoFqeusVUEG6d-GlAJLdpqJZk9w==" rel="nofollow" target="_blank">https://perspectivetherapeutics.com/newsroom/press-releases</a>.</p>  <p><b>About Perspective Therapeutics, Inc.</b></p>  <p align="justify">Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope <sup>212</sup>Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This &#34;theranostic&#34; approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.</p>  <p align="justify">The Company is advancing a portfolio of clinical-stage programs in the U.S., including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors).</p>  <p align="justify">The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary <sup>224</sup>Ra/<sup>212</sup>Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.</p>  <p align="justify">For more information, please visit the Company&#39;s website at <a href="https://www.globenewswire.com/Tracker?data=dFyKN_7GECffdnv1yWThU1vzf4zyndfPMFu6eT4QbnwcfFK3vHmuLy5U7CEyB5PAD9abzrHyXrE6KqL_nKnbPNNsXYLIcezz_3Zmnw2olz4A3FFA5bkwFTeRqawwzMJc" rel="nofollow" target="_blank">www.perspectivetherapeutics.com</a>.</p>  <p><b>Safe Harbor Statement</b></p>  <p align="justify">This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as &#34;may,&#34; &#34;will,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;anticipate,&#34; &#34;could,&#34; &#34;intend,&#34; &#34;target,&#34; &#34;project,&#34; &#34;estimate,&#34; &#34;believe,&#34; &#34;predict,&#34; &#34;potential,&#34; or &#34;continue&#34; or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include express or implied statements concerning, among other things, the expected benefits of the Company’s technologies and product candidates; and other statements that are not historical fact.</p>  <p align="justify">The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company&#39;s actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s preclinical and clinical development plans and clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and development activities; economic and market conditions may worsen; regulatory agencies may issue decisions that negatively impact the Company’s product candidates and clinical development plans; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading &#34;Risk Factors&#34; in the Company&#39;s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the &#34;SEC&#34;), in the Company&#39;s other filings with the SEC, and in the Company&#39;s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.</p>  <p><b>Media and Investor Relations Contacts:</b></p>  <p><b>Perspective Therapeutics IR:</b><br></br>Annie J. Cheng, CFA<br></br><a href="https://www.globenewswire.com/Tracker?data=6U29Ml8KThwgQwHMB1vhIt1ncxc696OQnPuOBRxbyuxiz82qM3vL9-QDe5JbhYo-LnLwNilbW-tCJS7TS-TG2_JoVdVannsHHoiLwxGMj3rJtjsFzB5E6b7Hn8V7MmfA" rel="nofollow" target="_blank">ir@perspectivetherapeutics.com</a></p>  <p><b>ENTENTE Network of Companies</b><br></br>Katie Morris, PhD<br></br><a href="https://www.globenewswire.com/Tracker?data=i0kaJTitlzB8mynfDhovVWLzSU9LXCkiDTi_LWn2iOlQ21ATXAwJGP4iM0ia-vxno5BPqvcwtlHjV9B-edgR1_QLU84qykATEoOI3-ZZGwb3-XU4yn4cpmxlAr33Kv_a" rel="nofollow" target="_blank">katiemorris@ententeinc.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgwMTE3NiM3NzUxOTg3IzUwMDAyODY4Mw=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YjFkN2VlMjUtZTA2NS00YTk1LWFhOTEtN2Q0MWFhN2ZmNmI3LTUwMDAyODY4My0yMDI2LTA3LTMxLWVu/tiny/Perspective-Therapeutics-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/e8b42463-3d31-441e-8c09-6b88826fe1c6"><img src="https://ml.globenewswire.com/media/e8b42463-3d31-441e-8c09-6b88826fe1c6/small/persp-jpg.jpg" border="0" width="150" height="31" alt="Primary Logo"></img></a></p>

Perspective Therapeutics (CATX) will report Q2 2026 results and provide a business update on Aug 10 after the close. The company emphasizes its 212Pb alpha-therapy platform and programs VMT-α-NET, VMT01, PSV359, plus expanding a Ra-212Pb generator network to support trials and potential commercialization. No financial figures are disclosed, making guidance and risk factors the key near-term focus.

News insight

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

AI summary

Sentiment rationale

Key facts

Earnings